David Hoang
Stock Analyst at Deutsche Bank
(4.68)
# 805
Out of 5,043 analysts
126
Total ratings
54.5%
Success rate
26.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRMY Harmony Biosciences Holdings | Reiterated: Hold | $39 → $42 | $40.28 | +4.27% | 9 | Oct 1, 2026 | |
| AXSM Axsome Therapeutics | Reiterated: Buy | $280 → $267 | $168.35 | +58.60% | 10 | Sep 29, 2026 | |
| ACAD Acadia Pharmaceuticals | Reiterated: Buy | $38 → $31 | $19.78 | +56.72% | 12 | Sep 25, 2026 | |
| XENE Xenon Pharmaceuticals | Downgraded: Hold | $90 → $46 | $36.44 | +26.23% | 10 | Sep 18, 2026 | |
| RYTM Rhythm Pharmaceuticals | Initiated Coverage: Hold | $120 | $90.78 | +32.19% | 1 | Aug 27, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $287 → $300 | $218.42 | +37.35% | 8 | Aug 26, 2026 | |
| SYRE Spyre Therapeutics | Reiterated: Buy | $135 → $127 | $85.69 | +48.21% | 5 | Aug 26, 2026 | |
| NBIX Neurocrine Biosciences | Rated: Hold | $190 → $165 | $142.44 | +15.84% | 12 | Aug 13, 2026 | |
| KYMR Kymera Therapeutics | Initiated Coverage: Hold | $120 | $112.40 | +6.76% | 1 | Jul 29, 2026 | |
| DNLI Denali Therapeutics | Rated: Buy | $31 → $35 | $19.45 | +79.95% | 10 | Jul 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $65 → $20 | $12.08 | +65.56% | 2 | Jun 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $420 → $374 | $259.86 | +43.92% | 9 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $12 → $14 | $17.85 | -21.57% | 23 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 → $45 | $40.61 | +10.81% | 3 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $7 | $2.14 | n/a | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $6.87 | n/a | 3 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $2.45 | n/a | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $220 | $232.68 | n/a | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $80 | $62.75 | n/a | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $24 → $3 | $9.31 | n/a | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $0.539 | n/a | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $73 | $331.61 | n/a | 1 | Mar 12, 2020 |
Harmony Biosciences Holdings
Oct 1, 2026
Reiterated: Hold
Price Target: $39 → $42
Current: $40.28
Upside: +4.27%
Axsome Therapeutics
Sep 29, 2026
Reiterated: Buy
Price Target: $280 → $267
Current: $168.35
Upside: +58.60%
Acadia Pharmaceuticals
Sep 25, 2026
Reiterated: Buy
Price Target: $38 → $31
Current: $19.78
Upside: +56.72%
Xenon Pharmaceuticals
Sep 18, 2026
Downgraded: Hold
Price Target: $90 → $46
Current: $36.44
Upside: +26.23%
Rhythm Pharmaceuticals
Aug 27, 2026
Initiated Coverage: Hold
Price Target: $120
Current: $90.78
Upside: +32.19%
Jazz Pharmaceuticals
Aug 26, 2026
Reiterated: Buy
Price Target: $287 → $300
Current: $218.42
Upside: +37.35%
Spyre Therapeutics
Aug 26, 2026
Reiterated: Buy
Price Target: $135 → $127
Current: $85.69
Upside: +48.21%
Neurocrine Biosciences
Aug 13, 2026
Rated: Hold
Price Target: $190 → $165
Current: $142.44
Upside: +15.84%
Kymera Therapeutics
Jul 29, 2026
Initiated Coverage: Hold
Price Target: $120
Current: $112.40
Upside: +6.76%
Denali Therapeutics
Jul 16, 2026
Rated: Buy
Price Target: $31 → $35
Current: $19.45
Upside: +79.95%
Jun 26, 2026
Rated: Buy
Price Target: $65 → $20
Current: $12.08
Upside: +65.56%
Jun 2, 2026
Reiterated: Buy
Price Target: $420 → $374
Current: $259.86
Upside: +43.92%
Mar 26, 2026
Reiterated: Sell
Price Target: $12 → $14
Current: $17.85
Upside: -21.57%
Nov 13, 2025
Reiterated: Buy
Price Target: $52 → $45
Current: $40.61
Upside: +10.81%
Jul 25, 2024
Initiated Coverage: Buy
Price Target: $7
Current: $2.14
Upside: n/a
Jul 17, 2024
Reiterated: Buy
Price Target: $16
Current: $6.87
Upside: n/a
Mar 6, 2024
Reiterated: Buy
Price Target: $16
Current: $2.45
Upside: n/a
Apr 26, 2023
Initiated Coverage: Hold
Price Target: $220
Current: $232.68
Upside: n/a
Apr 26, 2023
Initiated Coverage: Buy
Price Target: $80
Current: $62.75
Upside: n/a
Dec 7, 2022
Downgraded: Hold
Price Target: $24 → $3
Current: $9.31
Upside: n/a
Sep 30, 2020
Reiterated: Buy
Price Target: $19
Current: $0.539
Upside: n/a
Mar 12, 2020
Initiated Coverage: Buy
Price Target: $73
Current: $331.61
Upside: n/a